Navigation Links
Pharmaceuticals in Medical News

Watson Pharmaceuticals and Arrow Group Receive FTC Second Request

MORRISTOWN, N.J., Aug. 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today announced that it has received a request for additional information from the Federal Trade Commission ("FTC") in connection with Watson's...

Transcept Pharmaceuticals to Report Second Quarter 2009 Results

RICHMOND, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, ...

Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer

HOUSTON, Aug. 6 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is be...

Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection

SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin hydrochloride injection. IMS data indicates the combined U.S. market...

Addrenex Pharmaceuticals Announces Licensing Agreement With Dream Pharma

RESEARCH TRIANGLE PARK, N.C., Aug. 5 /PRNewswire/ -- Addrenex Pharmaceuticals, a specialty pharmaceutical company dedicated to developing treatments to regulate the adrenergic system, announced today an exclusive partnership with Dream Pharma. In keeping with its long-range plan to ...

Ferring Pharmaceuticals Announces Trade Name FIRMAGON(R) (degarelix for injection) for Advanced Prostate Cancer Treatment

PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. FIRMAGON...

Valeant Pharmaceuticals Reports Second Quarter Financial Results

ALISO VIEJO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX ) today announced second quarter financial results for 2009. "The second quarter once again demonstrated the strength of our diversified business model...

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

CARLSBAD, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ), the leader in antisense therapeutics, today announced that management will present a company overview at the 29th Annual Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009, ...

Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG

MORRISTOWN, N.J., Aug. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration...

Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments

SAN DIEGO, Aug. 3, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today reported financial results for the second quarter ended June 30, 2009. Arena reported a lower net loss allocable to common stockholders in the second quarter of 2009 of...

Quark Pharmaceuticals to Participate in IBC's Oligonucleotide Therapeutics: From Concept to Implementation Conference

FREMONT, Calif., Aug. 3 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will par...

MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results

MOUNTAIN VIEW, Calif., Aug. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced financial results for the second quarter ended June 30, 2009. The net loss for the quarter ended June 30, 2009 was $5.0 million, compared to $16.5 million durin...

Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)

EAST BRUNSWICK, N.J., Aug. 2 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) stating that the FDA can not at this time approve the Comp...

Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States

PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ) will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo ((R)) (zolpidem t...

Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.

CARLSBAD, Calif., July 31 /PRNewswire/ -- Excaliard Pharmaceuticals, a late stage preclinical company developing targeted therapeutics for the treatment of skin scarring and fibrotic disorders, is pleased to announce that Jay Birnbaum, Ph.D. has joined the Board of Directors as an Indep...

Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

SAN DIEGO, July 30, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today that the company is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on August 5, 2009 at 2:15 p.m. Eastern Time (11:15 a.m. Pa...

ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results

IRVINE, Calif., July 29 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it will release second quarter 2009 financial results after market close on August 5, 2009. In conjunction, the Company will host a conference call at 5:00 p.m. Eastern Time to disc...

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

DALLAS, July 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) , announced today that it is evaluating strategic options for the commercialization of MuGard in North America. MuGard is an FDA approved treatment for oral mucositis, a debilitat...

Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August

SOUTH SAN FRANCISCO, Calif., July 29 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a...

Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, August 3, 2009

SAN DIEGO, July 29, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) today announced it will report second quarter 2009 financial results after the NASDAQ Global Market closes on Monday, August 3, 2009. That same afternoon, Jack Lief, Arena's President and Chi...

Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook

MORRISTOWN, N.J., July 29 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leader in generic and specialty branded pharmaceuticals, today reported net income of $53.0 million, or $0.46 per diluted share. Excluding special items as detailed in the reconciliati...

Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results

THE WOODLANDS, Texas, July 28 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported fin...

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement

Nasdaq-Listed Biopharmaceutical Company Focusing on Improved Drug Targeting and Reformulation of Existing Therapeutic Compounds to Benefit Underserved Patient Populations NOVATO, Calif. and LA JOLLA, Calif., July 28 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Rapt...

Millennium Pharmaceuticals Inc./Lymphoma Research Foundation funds lymphoma research

New York, NY The Lymphoma Research Foundation (LRF) is pleased to announce that the 2009 Millennium Pharmaceuticals, Inc./Lymphoma Research Foundation Clinical Investigator Career Development Award has been awarded to Kai Fu, MD, PhD, Associate Professor at the Nebraska Medical Center in Omaha, Ne...

Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma

FREMONT, Calif., July 27 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced data suggesting that QPI-1007 prevents progressive retinal ganglion cell (RGC) loss in ...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

DALLAS, July 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that its European partner, SpePharm , has commenced commercial launch of MuGard in Norway. This follows previous commercial launches in the UK, Germ...

Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors

SOUTH SAN FRANCISCO, Calif., July 27 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today announced that Helen S. Kim has been appointed to the company's Board of Directors, effective immediately. Ms. Kim is a designee of New Enterprise Associates, which p...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference Access to Provide Details on MuGard Launch in Europe ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will pres...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

DALLAS, July 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will present at the Jesup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thu...

Transcept Pharmaceuticals to Present at BMO Capital Markets Healthcare Conference on August 5, 2009

RICHMOND, Calif., July 22 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT ), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, a...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

DALLAS, July 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will present at the Jessup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Th...

Amylin Pharmaceuticals Reports Second Quarter Financial Results

SAN DIEGO, July 21 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) today reported financial results for the quarter ended June 30, 2009. The Company reported total revenue of $209.4 million for the quarter ended June 30, 2009, which includes net pr...

Valeant Pharmaceuticals to Announce 2009 Second Quarter Results on August 4, 2009

ALISO VIEJO, Calif., July 21 /PRNewswire-FirstCall/ --Valeant Pharmaceuticals International (NYSE: VRX ) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Tuesday, August 4, 2009 at 10:00 a.m. EDT (7:00 a.m. PDT) to...

Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results

Wednesday, August 5, 2009 9:00 a.m. EDT 1-800-731-5774 Webcast: http://www.nucryst.com/web_casts.htm PRINCETON, NJ, July 21 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp. invi...

Avidas(TM) Pharmaceuticals and LaRon(TM) Pharma Inc. Announce Co-Promotion Agreement

DOYLESTOWN, Pa., July 21 /PRNewswire/ -- Avidas Pharmaceuticals and LaRon Pharma Inc. today announced that they have entered into an agreement for LaRon to co-promote Avidas' key prescription-only convenience kits, Avidoxy(TM) DK defence kit and Scalacort(TM) DK defence kit. Under the te...

Raptor Pharmaceuticals Corp. to Present at 2009 Cystinosis Research Network Family Conference

NOVATO, Calif., July 16 /PRNewswire-FirstCall/ -- Raptor Pharmaceuticals Corp. ("Raptor" or the "Company") (OTC Bulletin Board: RPTP), today announced that Patrice P. Rioux, M.D., Ph.D., Raptor's Chief Medical Officer, will present an update on the Company's ongoing Phase 2b study of del...

Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever

SAN DIEGO, July 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX ) announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever in adults...

Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA

MORRISTOWN, N.J., July 14 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application ...

Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009

TUSTIN, Calif. , July 14 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ), today announced financial results for the fourth quarter and fiscal year (FY) 2009 ended April 30, 2009. Total revenues for the fourth quarter of FY 2009 in...

Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

SOUTH SAN FRANCISCO, Calif., July 13 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that it has ...
Other Tags
(Date:8/1/2014)... Charan Ranganath of the UC Davis Center for ... National Security Science and Engineering Faculty Fellowship from ... million fellowship will support new work on learning ... UC Davis. , The new project aims to ... with activity in the cortex and hippocampus, brain ...
(Date:8/1/2014)... is tricky enough. Knowing what causes them at the ... of Iowa researchers have created the most detailed map ... long associated with blinding diseases, such as age-related macular ... in the choroid, which supplies blood and oxygen to ... differences in the abundance of proteins in different areas ...
(Date:8/1/2014)... 2014 The Journal of Nutrition Education and Behavior ... Educational Material (GEM) awards, which were presented at the ... "Nutrition Education Impact: Local to Global," in Milwaukee, Wisconsin, ... awards recognize the authors of the best article and ... by members of the JNEB Journal Committee and Board ...
Breaking Biology News(10 mins):A map for eye disease 2
(Date:8/1/2014)... Diego School of Medicine report that dietary capsaicin ... activation of a receptor on cells lining the intestines ... risk of colorectal tumors. , The findings are published ... Journal of Clinical Investigation . , The receptor or ... neurons, where it acts as a sentinel for heat, ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, ... manufacturing jobs may have significantly less endurance than those who weigh ... people -- half were obese, half were of normal weight -- ... 60 percent longer. Obesity also was associated with less strength, ... older -- 50 to 65 years of age -- neither improved ...
(Date:8/1/2014)... Ohio In a first-of-its-kind study, researchers at University ... that lap infants may be at greater risk for ... pediatric medical emergencies on flights worldwide between January 2010 ... occurred in children under the age of 2. ... to characterize the rare event of an in-flight pediatric ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 As AndroGel ... the country, Ronald E. Johnson, Jr. has been appointed ... AndroGel and other testosterone medications. Since the Fall of ... P.S.C. have worked diligently to investigate and prosecute the ... embolisms, and blood clots as a result of taking ...
(Date:8/1/2014)... Texas (PRWEB) August 01, 2014 ... health coverage and healthcare reforms are boosting healthcare ... of medicines through discounts and increasing generic consumption ... at approximately 76.7 million in 2013, having grown ... 1.4%, from 2008. The implementation of the Health ...
Breaking Medicine News(10 mins):Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3Health News:New research characterizes in-flight pediatric deaths 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4
Other Contents